Bone Disorders

• EMA approval · 2023-06-01
  EMA Authorised: Zoledronic acid Actavis (zoledronic acid monohydrate) — Actavis Group PTC ehf

  The EMA authorised Zoledronic acid Actavis (zoledronic acid monohydrate) for therapeutic use in fractures and bone-related conditions.

• CLINICAL_TRIALS research · 2019-02-06
  Clinical Trial Update: Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis [Phase 4]

  Phase 4 trial evaluating effects of oral versus non-oral contraceptives on the GH/IGF-1 axis; completed with results posted in 2019.

• CLINICAL_TRIALS trial_result · 2018-12-04
  Clinical Trial Update: Post-Market Clinical Investigation of NanoFUSE® Bioactive Matrix [Phase 4]

  Phase 4 post-market clinical investigation update for NanoFUSE Bioactive Matrix (bone-related conditions).